Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations

Frontiers in Medicine

Adelheid Fankhauser¹  Francesca Borgna²  Zeynep Talip²  Cristina Müller³  Roger Schibli³  Nicholas P. van der Meulen⁴  Thierry Stora⁵  Eric Chevallay⁵  Valentin N. Fedosseev⁵  Shane G. Wilkins⁵  Bruce Marsh⁵  Laura Lambert⁵  Pascal Fernier⁵  Joao P. Ramos⁶  Charlotte Duchemin⁶  Vadim Gadelshin⁷  Ulli Köster⁸  Frederic Juget⁹  Youcef Nedjadi⁹  Claude Bailat⁹  Jiri Ulrich^1,10  Dmitry Fedorov^1,11 

[1] Analytic Radioactive Materials, Paul Scherrer Institute, Villigen, Switzerland;Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland;Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland;Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland;Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland;Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen, Switzerland;European Organization for Nuclear Research (CERN), Geneva, Switzerland;European Organization for Nuclear Research (CERN), Geneva, Switzerland;Institute for Nuclear and Radiation Physics, Catholic University of Leuven, Leuven, Belgium;European Organization for Nuclear Research (CERN), Geneva, Switzerland;Institute of Physics, Johannes Gutenberg University, Mainz, Germany;Institute of Physics and Technology, Ural Federal University, Yekaterinburg, Russia;Institut Laue-Langevin, Grenoble, France;Institute of Radiation Physics, University Hospital and University of Lausanne, Lausanne, Switzerland;Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen, Switzerland;Petersburg Nuclear Physics Institute, National Research Center Kurchatov Institute, Gatchina, Russia;

关键词: Er-169;    electromagnetic isotope separation;    lanthanide-separation;    activity standardization;    in vitro;    laser resonance ionization;   

DOI  :  10.3389/fmed.2021.643175

来源: Frontiers

【 摘 要 】

The β−-particle-emitting erbium-169 is a potential radionuclide toward therapy of metastasized cancer diseases. It can be produced in nuclear research reactors, irradiating isotopically-enriched 168Er2O3. This path, however, is not suitable for receptor-targeted radionuclide therapy, where high specific molar activities are required. In this study, an electromagnetic isotope separation technique was applied after neutron irradiation to boost the specific activity by separating 169Er from 168Er targets. The separation efficiency increased up to 0.5% using resonant laser ionization. A subsequent chemical purification process was developed as well as activity standardization of the radionuclidically pure 169Er. The quality of the 169Er product permitted radiolabeling and pre-clinical studies. A preliminary in vitro experiment was accomplished, using a 169Er-PSMA-617, to show the potential of 169Er to reduce tumor cell viability.

【 授权许可】

CC BY